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Summary
OBJECTIVE: About 50% of acute coronary syndromes oc-
cur in patients classified as being at low coronary risk. We
aimed to assess the potential preventive benefit of carotid
plaque imaging with ultrasound.
METHODS: We assessed the prevalence of “old” arteries
(vascular age ≥70 years; VA70) in 3248 healthy subjects
aged 40–65 years from the Swiss region of Olten and
the German region of Koblenz. We compared sensitivity,
specificity and discriminatory performance of SCORE,
PROCAM and AGLA coronary risk calculators to detect
VA70 for various decision thresholds and performed re-
classification and cost-efficiency analysis.
RESULTS: VA70 was found in one out of eight subjects.
Sensitivity for VA70 was 6% at the 10% AGLA threshold in
women and 30% in men in the Olten area, which was con-
firmed for the Koblenz area with PROCAM (sensitivity 8%
in women, 56% in men). Results were similar for SCORE.
The discriminatory performance ranged between 0.69 and
0.82. Reclassification from low risk to a higher risk catego-
ry occurred in 17–35% of patients. Analysis showed that
carotid imaging for CHF 100 per person was highly cost
efficient.
CONCLUSIONS: In subjects aged 40–65 years, the
prevalence of old arteries is one out of eight and the de-
tection rate of AGLA and SCORE is lower in women (6%
for PROCAM) than for men (30%) at the 10% thresh-
old. Carotid imaging may be used to reclassify subjects
from low to intermediate or high cardiovascular risk. Our
method is highly cost efficient at a price of CHF 100 per
examination.
Keywords: primary prevention, atherosclerosis, carotid
plaque, vascular age, accuracy of risk calculators
Introduction
In Switzerland, every second case of acute coronary syn-
drome occurs in primary care subjects classified as being
at low coronary risk according to the Swiss Atherosclerosis
Association (Arbeitsgruppe Lipide und Atherosklerose;
AGLA) [1]. This was found in a large national Swiss study,
where the sensitivity at the 5% SCORE level was only
37% in patients presenting with a first acute coronary syn-
drome [1] (SCORE = Systematic COronary Risk Evalu-
ation). A “present time” assessment from Copenhagen of
the diagnostic accuracy of coronary risk calculators at var-
ious risk thresholds, derived from patients admitted for a
first myocardial infarction, confirmed the Swiss observa-
tions by Selby [2, 3]: a low sensitivity for cardiovascular
events was found in the prospective Copenhagen General
Population Study, in which 68 fatal and 767 fatal or non-
fatal cardiovascular events occurred over an observation
time of 7 years. Sensitivity at the 5% SCORE level was
42% and 26% for fatal and fatal or nonfatal events, respec-
tively [2].
For prevention of cardiovascular events in primary care,
the trade-off between sensitivity and specificity is impor-
tant. If sensitivity thresholds are lowered, the risk of treat-
ing healthy subjects who will never experience a clinical
event increases and cost efficiency decreases. At the cur-
rent decision thresholds for statin intervention – 10% risk
according to AGLA and low density lipoprotein (LDL)
>3.0 mmol/l – the specificity of such interventions is high,
but sensitivity is low [4].
Atherosclerotic plaques indicate high-risk patients with
very high specificity [5] and may therefore improve the
poor sensitivity of cardiovascular risk scores without loss
in specificity. For the purpose of this study, we defined
“old” arteries as a vascular age of 70 years or more (VA70),
because this corresponds to a highly specific cut-off for the
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occurrence of myocardial infarction as evidenced in a large
cohort study of 6336 male and female persons [5]. We as-
sessed the diagnostic accuracy of PROCAM/AGLA (PRO-
CAM = Prospective Cardiovascular Münster-Studie) and
SCORE to detect VA70 in a group of healthy women and
men (age range 40–65 years) in Olten (Switzerland) and
the Koblenz area in Germany. Given the known limitations
in the sensitivity of PROCAM/SCORE among younger
healthy subjects [3, 6], the study further investigated how
cardiovascular disease prevention decisions might change
if results from carotid atheroma scanning with ultrasound
were known and if such an approach is cost efficient.
Materials and methods
Outcome measure
The outcome measure was vascular age of 70 years or
more (VA70) in healthy women and men aged 40–65 years
who were not taking statins or antihypertensive drugs.
Subject selection
Subjects were assessed at the practice level as described
elsewhere [7]. The selection process is outlined in figure 1.
In the imaging centre in Olten, subjects were referred by
their primary care physician (58%) or self-referred (42%)
to the vascular risk foundation [8]. In the imaging centre in
Koblenz, all subjects were referred within a working med-
icine setting [9]. Subjects had to be free of cardiovascu-
lar symptoms or disease and not currently treated for high
blood pressure or cholesterol. The time range and the me-
dian time of assessment were between 2002 and 2017 in
the Olten area (median year 2009) and between 2008 and
2017 in the Koblenz area (median year 2012). Laboratory
values, blood pressure and medical history were measured
locally and entered into a spread-sheet (Excel, Microsoft,
Richmond, USA).
Carotid imaging
The burden of longitudinal carotid plaque surface was im-
aged with a high-resolution ultrasound linear transducer
probe (7.5–12.0 MHz), which identified plaques with in-
timal thickening ≥1.0 mm. The longitudinal area of all
Figure 1: Patient selection from the Arteris Group.
plaques was summed to give the total plaque area (TPA)
in mm2. All TPA measurements were made by M.R. in
Olten and by A.A. in Koblenz. Intraobserver reproducibil-
ity by M.R. for both carotid arteries in 57 patients showed
a correlation coefficient of r2 = 0.964 (left carotid artery:
r2 = 0.944, both arteries r2 = 0.976, supplementary fig.
S1 in appendix 1). For the cut-offs of TPA 0–9, 10–49,
50–99 and ≥100 mm2, the linear weighted intraobserver
kappa value was good at 0.80 (95% confidence interval
[CI] 0.69–0.90). Interobserver variability was not formally
assessed (no trained staff besides M.R. in Switzerland). In-
traobserver reproducibility was tested for both carotid ar-
teries in 56 patients for A.A. with a correlation coefficient
of r2 = 0.976 (left carotid artery: r2 = 0.949, both arteries r2
= 0.953). For the cut-offs of TPA 0–9, 10–49, 50–99 and
≥100 mm2, the linear weighted kappa value was very good
at 0.97 (95% CI 0.92–1.00).
Computation of vascular age
The mean values of TPA derived from 5-year intervals for
1500 men and women aged 35 to 79 years were plotted
against their chronological age, as previously described
[7]. An exponential function was added, which connected
these 5-year intervals, and the equation of the line was dis-
played. These exponential equations describing TPA (y) as
a function of age (x) were solved for x in order to deter-
mine the vascular age for men and women separately [7].
The distribution of VA70 was counted for low, intermedi-
ate and high cardiovascular risk for PROCAM/AGLA and
SCORE.
Computation of cardiovascular risk
SCORE risk was computed using the published risk for-
mulae in an Excel spread sheet for low risk populations
[10]. SCORE intermediate risk is defined as between 1.0
and 4.9% [11]. According to European guidelines, more in-
tensive primary prevention activities are needed in subjects
with a high SCORE (above 5%).
PROCAM risk was calculated online, since the formula for
risk calculations is kept secret [12]. For Switzerland, PRO-
CAM risk was multiplied by the factor 0.7 (according to
the Swiss AGLA guidelines 2014 [13]) in order to calcu-
late the AGLA risk. For Switzerland, it is recommended
that an AGLA risk below 10% should be viewed as a low
coronary risk. We used several sensitivity thresholds in or-
der to calculate the sensitivity and specificity to diagnose
VA70.
Computation of reclassification
First, SCORE was recalculated with vascular age instead
of chronological age, if the vascular age were higher than
the chronological age. Only low risk subjects (SCORE
risk <1.0%) were analysed and the numbers shifted to a
SCORE risk of 1% or more were counted as subjects re-
classified to a higher risk level. This calculation was not
available for PROCAM, because the calculations are not
publicly available and repeat calculations for vascular age
were time consuming.
Second, for better comparability, post-test risk was calcu-
lated for SCORE and PROCAM using the Bayes formula,
based on the sensitivity and specificity of TPA, which were
derived from the Tromsø study [5, 14] and based on per-
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sonal communication of the raw data. Subjects were count-
ed as reclassified with PROCAM if their risk was changed
from <10% to 10% or more, and were reclassified with
SCORE if their risk was changed from <1.0% to 1.0% or
more.
Computation of cost efficiency
We used a cost-efficiency analysis developed by the vascu-
lar risk foundation (personalised price model, PEP), which
is based on an estimate of avoidable direct and indirect
costs of a cardiovascular event, and compared the results
with the quality-adjusted life year (QALY) model for
statins of the Swiss Medical Board [15, 16]. The major in-
put variables of the two models were kept identical and
were: (1) average LDL and cardiovascular risk of reclas-
sified subjects, (2) 50% LDL reduction at a cost of 0.68
CHF/day (the effect of 20 mg rosuvastatin per day), (3)
cost of imaging of carotid arteries CHF 100, (4) effect
of statins: 22%/35% relative risk reduction (RRR) per 1
mmol/l LDL reduction [17, 18]. The PEP model calculates
indirect and direct costs of a cardiovascular event as being
CHF 200,000 over 10 years as follows [19]: direct and in-
direct costs were CHF 4.8 billion for myocardial infarction
and CHF 3.2 billion for stroke in 2011 in Switzerland [20].
The Swiss death statistics of the Federal Office of Statistics
showed 8150 due to ischaemic heart disease; further, an in-
cidence of 150 strokes per 100,000 habitants (n = 11,850)
are expected to occur, of which around 20% are fatal [21].
The risk of second and further events after a first event
is 34% for myocardial infarction and 24% for stroke in 5
years [22], which leads to average costs of CHF 251,622
per cardiovascular event. For the purpose of this study, we
used total costs per event of CHF 200,000, which is there-
fore a conservative estimate. For further details refer to our
calculator online [19]. The calculation of cost efficiency
used by the Swiss Medical Board has been described else-
where [16], as follows. “For one fatal cardiovascular event
(myocardial infarction, stroke, coronary revascularisation),
4.5 nonfatal events occur. The cost is CHF 8500 per fatal
event and CHF 25,000 per nonfatal event in the first year
and CHF 8000 in subsequent years. Loss of QALYs is 1.0
for fatal and 0.2 for nonfatal events. The annual preventive
medical cost per individual, including statin costs, is CHF
470, all cardiovascular events occur uniformly after 50%
of the total observation time of 5 years. Loss of QALY at
2.5 years was therefore 2 × 2.5 ×1 = 5.0 QALY for fatal
events and 9 × 2.5 × 0.2 = 4.5 QALYs for nonfatal events,
and thus 5.0 + 4.5 = 9.5 QALYs in 1000 persons or 0.0095
QALYs per person. When this effect model is applied to a
10-year period, then 4 fatal events and 18 nonfatal events
can be prevented; therefore, 4 × 5 × 1 = 20 QALYs for
fatal and 18 × 5 × 0.2 = 18 QALYs for nonfatal events, or
a total of 38 QALY losses, can be prevented in 1000 per-
sons, which is 0.038 QALYs per person. Therefore, the ef-
fect model is 4 times higher in 10 years when compared
with 5 years.”
Clinical example
Figure 2 shows the measurement of a plaque area through
tracing the longitudinal surface of a carotid plaque (23
mm2). A plaque area of 23 mm2 corresponds to a vascular
age of 34 years in men and 43 years in women. VA70 cor-
responds to a total plaque area of 108 mm2 in men and 66
mm2 in women. This represents high risk atherosclerosis:
VA70 = 99th percentile for men (sensitivity 9%, specifici-
ty 97%) and 99th percentile for women (sensitivity 18%,
specificity 95%) in the Tromsø study (n = 6226, with fol-
low up of 6 years, 297 myocardial infarctions during fol-
low up [2]. Bayes post-test risk [23] of VA70: for 4%
AGLA 11% in men, 13% in women; for 10% AGLA: 25%
in men and 29% in women. Therefore, VA70 transforms
low into intermediate and intermediate into high cardiovas-
cular risk.
C-statistics of cardiovascular risk calculators
We determined the diagnostic accuracy of AGLA/PRO-
CAM and SCORE to detect VA70 using receiver operating
curves (ROCs) and derived the areas under the curves
(AUCs) separately for sex and geographical region.
Ethical aspects
Subjects self-referred to the Vascular Risk Foundation
gave written consent. The study protocol was approved by
the local ethics committee of Solothurn, Switzerland. Prac-
tice-based subjects were entered into an anonymised study
registry, for which current legislation in Switzerland and
Germany does not require formal ethics committee con-
sent.
Potential bias
The selection of our subjects was not based on a random
population sample. Our results pertain to the primary care
setting described.
Statistics
We compared subjects with and without VA70 by means
of an independent samples t-test for statistical analysis.
For comparisons of cardiovascular risk, we used the rank-
Figure 2: Vendor independent easy to perform measurement of TPA using the surface tool, resulting in an area of 23 mm2, which would corre-
spond to an vascular age of 34 years in men and to an vascular age of 43 years in women. VA70 corresponds to a total plaque area of 108
mm2 in men and 66 mm2 in women, indicating advanced carotid atherosclerosis.
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sum test because risk was not normally distributed even af-
ter log-transformation. MedCalc software (Version 16.8.4)
was also used to calculate and compare ROCs [24]. The
level of statistical significance was set at p <0.05.
Results
Patient selection and clinical characteristics
We assessed 5383 healthy German and Swiss subjects aged
20–80 years from the Arteris Group. We excluded 1265
subjects who were outside the pre-specified age range of
40 to 65 years, and we further excluded 870 subjects who
were taking statins or antihypertensive treatment at the
time of the cross-sectional observation (fig. 1). Therefore,
3248 subjects remained for further evaluation.
Clinical and ultrasound information from carotid plaques
for Olten area subjects (n = 1429) was collected and com-
pared with 1819 Koblenz area subjects.
Olten area subjects were older (54, standard deviation [SD]
7 vs 50 [SD 6] years) with comparable results for the num-
bers of females and current smokers in each group, and for
systolic blood pressure, lipids, and global risk scores (table
1).
Average 10-year risk among groups was low (SCORE CH
1.6%, SD 1.6%; SCORE DE 1.2%, SD 1.2%). In the Olten
area, the prevalence of vascular age ≥70 (VA70) was 12%
in women and 11% in men (11 and 14%, respectively, in
the Koblenz area) and was one in eight for the entire popu-
lation.
VA70 was defined as a TPA of 66 mm2 in women and of
108 mm2 in men, corresponding to the 99th percentile for
each gender group in the Tromsø cohort (n = 6226, person-
al communication) and corresponding to the 80th and 86th
percentile, respectively, in the Arteris cohort (n = 5383,
supplementary table S1 in appendix 1).
Frequency distribution of subjects with VA70 accord-
ing to PROCAM/AGLA risk category
Most subjects with VA70 were classified as low risk ac-
cording to PROCAM/AGLA (Olten area 82%, 70% with-
out calibration factor of 0.7; Koblenz area 57%). For
SCORE, 20% of patients with VA70 were in the low risk
group (<1% risk), but only 12% were classified as high-
risk patients (5% risk or more) (table 2).
Comparison of subjects with and without VA70
Subjects with VA70 (n = 394) were significantly older and
were more frequently current smokers (39 vs 22%). High-
ly significant differences (p <0.0001) for total cholesterol,
LDL cholesterol, blood pressure, and SCORE and PRO-
CAM were found (table 3). In patients with VA70, the av-
erage vascular age in women was 79 years and 76 years in
men.
Table 1: Clinical characteristics of the Arteris Group subjects (age 40–65, primary care, no statin or antihypertensive drug use).
Olten area group Koblenz area group
Number of subjects (n) 1429 1819
Female, n (%) 679 (48) 640 (35)
Mean age, years (SD) 53.9 (6.7) 49.8 (6.1)
Family history of CAD, n (%) 273 (19) 408 (22)
Current smoker, n (%) 332 (23) 435 (24)
Blood pressure systolic, mm Hg, mean (SD) 127 (15) 123 (15)
TPA mm2, mean (SD) 42 (41) 39 (49)
Individuals with vascular age ≥ 70 165 (12) 229 (13)
Total cholesterol, mmol/l, mean (SD) 6.0 (1.2) 6.0 (1.1)
HDL cholesterol, mmol/l, mean (SD) 1.5 (0.5) 1.5 (0.4)
LDL cholesterol, mmol/l, mean (SD) 3.8 (1.0) 3.9 (0.9)
Triglycerides, mmol/l, mean (SD) 1.5 (0.9) 1.7 (1.2)
SCORE, 10-year risk in % (SD) 1.6 (1.6) 1.2 (1.2)
PROCAM, 10-year risk in % (SD) 5.2 (6.3) 5.0 (6.5)
AGLA, 10-year risk in % (SD) 3.7 (4.4)
CAD = coronary artery disease; HDL = high density lipoprotein; LDL = low density lipoprotein; SD = standard deviation; TPA = total plaque area
Table 2: Frequency distribution of VA70 among risk categories.
n %
CH-AGLA 0.0–9.9% 135 82
CH-AGLA 10.0–19.9% 23 14
CH-AGLA ≥20.0% 7 4
Sum 165 100
DE-PROCAM 0.0–9.9% 130 57
DE-PROCAM 10.0–19.9% 62 27
DE-PROCAM ≥20.0% 37 16
Sum 229 100
SCORE 0.00–0.99 78 20
SCORE 1.00–4.99 270 69
SCORE ≥5.00 46 12
Sum 394 100
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Sensitivity and specificity of high-risk cardiovascular
risk thresholds for the detection of VA70
At current intervention thresholds (AGLA/PROCAM
≥10% 10-year risk, SCORE ≥ 5% 10-year risk), the sen-
sitivity to detect VA70 was 6% (95% CI 2–14%) in Olten
area women (higher in men at 30%, 95% CI 21–41%) and
was 8% (95% CI 3–18%) in women from the Koblenz
area (higher in men at 56%, 95% CI 48–64%); similarly,
for SCORE, sensitivity for women from the Olten area
was 5% (18% in men) and was 0% for women from the
Koblenz area (16% in men) (table 2). For lower-risk de-
cision thresholds, sensitivity increased and specificity de-
creased: for AGLA 2%, sensitivity was 54% in women
(90% in men) in the Olten area and for PROCAM 2%
was 47% in women and 96% in men in the Koblenz area.
On the other hand, for VA70 specificity was very high in
women (99–100%) and in men (83–94%) at the decision
thresholds of 10 and 5% (table 4).
Reclassification and numbers needed to image
Reclassification with vascular age
Using SCORE in women, 17% were shifted from low risk
to intermediate or high risk on the basis of their vascular
age (21% men) (table 5).
Reclassification with Bayes theorem
Using PROCAM In women, 7% were shifted from low risk
to intermediate or high risk using their vascular age (20%
men). The number needed to image was 13.5 in women
(5.1 in men). In women using SCORE, 28% were shifted
from low risk to intermediate or high risk using their vas-
cular age (35% men). The number needed to image was 3.6
in women (2.9 in men) (table 5).
Cost-efficiency analysis
The inclusion of imaging costs was cost effective for both
the PEP and the QALY model, even with a lower RRR of
Table 3: Comparison of Group 1 (VA70 present) and Group 2 (VA70 absent).
Group 1 Group 2 p-value
Number of subjects (n) 394 2854
Female, n (%) 144 (37) 1175 (41) 0.0800
Age women, mean (SD) 57.0 (5.8) 51.6 (6.7) <0.0001
Age men, mean (SD) 55.5 (5.6) 50.5 (6.4) <0.0001
Vascular age women, mean (SD) 79.2 (7.9) 35.8 (16.4) <0.0001
Vascular age men, mean (SD) 76.9 (6.4) 39.5 (16.6) <0.0001
Family history of CAD, N (%) 93 (24) 588 (21) <0.0001
Current smoker, N (%) 153 (39) 614 (22) <0.0001
Blood pressure, mm Hg, mean (SD) 132 (18) 124 (15) <0.0001
TPA, mm2, mean (SD) 131 (51) 28 (26) <0.0001
Total cholesterol, mmol/l, mean (SD) 6.4 (1.6) 6.0 (1.1) <0.0001
HDL cholesterol, mmol/l, mean (SD) 1.4 (0.4) 1.5 (0.4) 0.0001
LDL cholesterol, mmol/l, mean (SD) 4.2 (1.1) 3.8 (0.9) <0.0001
Triglycerides, mmol/l, mean (SD) 1.7 (1.1) 1.6 (1.1) 0.0043
PROCAM, 10-year risk in % (SD) 9.9 (9.6) 4.4 (5.5) <0.0001
SCORE, 10-year risk in % (SD) 2.6 (2.1) 1.2 (1.3) <0.0001
CAD = coronary artery disease; HDL = high density lipoprotein; LDL = low density lipoprotein; SD = standard deviation; TPA = total plaque area
Table 4: Sensitivity (Sens) and specificity (Spec) of AGLA, PROCAM, and SCORE to detect VA70 at various decision cut-offs for female and male subjects from the Olten area
and the Koblenz area including 95% confidence intervals (Note: AGLA = PROCAM × 0.7).
Olten area Female Male Female Male Female Male Female Male Female Male
AGLA 2% AGLA 4% AGLA 6% AGLA 8% AGLA 10%
Sens 54 (42–65) 90 (82–96) 33 (23–44) 72
(61–82)
16 (9–26) 53
(42–64)
11 (5–20) 40
(29–51)
6 (2–14) 30
(21–41)
Spec 77 (73–80) 30 (26–33) 92 (90–94) 57
(53–61)
96 (95–98) 73
(70–77)
98 (96–99) 81
(78–84)
99 (97–99) 87
(84–89)
SCORE 1% SCORE 2% SCORE 3% SCORE 4% SCORE 5%
Sens 73 (62–82) 95 (88–99) 33 (23–44) 76
(65–85)
15 (8–24) 52
(41–63)
10 (4–18) 31
(22–42)
5 (1–12) 18
(11–28)
Spec 67 (63–71) 31 (28–35) 89 (86–92) 59
(56–63)
97 (96–98) 79
(76–82)
99 (98–100) 90
(87–92)
99 (98–100) 94
(92–96)
Koblenz Area Female Male Female Male Female Male Female Male Female Male
PROCAM 2% PROCAM 4% PROCAM 6% PROCAM 8% PROCAM 10%
Sens 47 (34–60) 96 (92–98) 21 (12–33) 86
(80–91)
11 (5–22) 75
(68–82)
8 (3–18) 63
(68–82)
8 (3–18) 56
(48–64)
Spec 84 (81–87) 24 (22–27) 94 (92–96) 50
(47–53)
97 (95–98) 66
(63–69)
98 (97–99) 78
(75–80)
99 (98–100) 83
(81–86)
SCORE 1% SCORE 2% SCORE 3% SCORE 4% SCORE 5%
Sens 35 (24–49) 92 (87–96) 10 (4–20) 65
(58–73)
2 (0–9) 40
(32–47)
0 (0–6) 26
(19–33)
0 (0–6) 16
(10–22)
Spec 90 (88–93) 52 (49–56) 97 (95–98) 79
(77–82)
99 (98–100) 91
(89–93)
100 (99–100) 96
(95–97)
100 (99–100) 98
(97–99)
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active treatment of 22% per 1 mmol/l LDL reduction. Us-
ing SCORE or PROCAM, there was a cost saving of be-
tween about CHF 2400 and CHF 21,000 per avoided event.
Cost/QALY were within commonly accepted thresholds of
150,000 CHF/QALY or resulted even in a return on invest-
ment, such as in women assessed with PROCAM (table
6a). The calculation of different models for a 22% RRR
with LDL reduction of 1.0 mmol/l resulted in a cost-effi-
ciency threshold for imaging between 940 and 3200 CHF
per imaged patient (table 6b).
C-statistics of cardiovascular risk calculators
We assessed the diagnostic accuracy of PROCAM and
SCORE to detect women and men with VA70 by geo-
graphical region. Per region and sex, there were no signifi-
cant differences between risk measurement tools (SCORE/
PROCAM) (table 7).
Discussion
We found a clinically relevant prevalence of old arteries
(VA70), a highly specific marker for future myocardial in-
farction, in one out of eight of 3238 practice-based healthy
subjects aged 40–65 years. In the Olten area, 543 had a low
risk of <10%, defined with AGLA, and VA70 was found in
135 out of 165 (82%) of these low risk subjects (table 2).
In the Koblenz area, 1543 subjects had a low risk of <10%
defined with PROCAM, and VA70 was found in 130 out
of 229 (57%). Therefore, high-risk carotid plaque (VA70)
shows the highest frequency distribution in subjects clas-
sified as low risk by PROCAM/AGLA. Further, only 12%
of subjects with VA70 were classified as high-risk patients
by SCORE (table 2).
This finding raises several important questions about the
allocation of resources in preventive medicine, which is
traditionally focused on high-risk patients, despite the fact
that most cardiovascular events occur in low-risk subjects,
as shown in Switzerland [1] and in Denmark [3, 25].
Therefore, carotid imaging, as well as observational stud-
ies, have congruently revealed that a focus on high-risk pa-
tients, as proposed by the Swiss Medical Board [15], fails
by a large proportion to identify most patients at risk and is
therefore unable to reduce the cardiovascular disease bur-
den imposed on individuals and society. Important issues
about sensitivity of cardiovascular risk charts to trigger in-
Table 5: Reclassification based on carotid atherosclerosis in low risk subjects calculated for sex and risk assessment tool (SCORE/PROCAM) using either vascular age
(SCORE only) or Bayes theorem (SCORE and PROCAM).
Reclassification with SCORE and PROCAM Female Male
n % 10-year risk LDL n % 10-year risk LDL
Low risk by SCORE 983 100 0.3 3.6 755 100 0.6 3.7
Reclassification to higher risk by arterial age 163 17 3.6 3.8 155 21 3.4 3.8
Reclassification to higher risk by Bayes theorem 274 28 1.7 3.9 261 35 1.4 3.8
Number needed to image with Bayes Theorem 3.6 2.9
Low risk by AGLA/PROCAM 1293 100 1.4 3.7 1552 100 3.8 3.7
Reclassification to higher risk by Bayes theorem 96 7 15.6 4.8 305 20 14.5 4.1
Number needed to image with Bayes
theorem
13 5
Table 6: a: Cost-efficiency analysis in CHF based on the personalised price (PEP) and cost per quality adjusted life-year (QALY) models.
SCORE PROCAM
Female Male Female Male
Number needed to image 3.6 2.9 13.5 5.1
ROI per patient / PEP model 35% RRR −8784 −6319 −21,306 −16,718
ROI per patient / PEP model 22% RRR −3982 −2466 −11,445 −8,888
Cost/QALY model 35% RRR per patient 8588 16,789 −5784 −4686
Cost/QALY model 22% RRR per patient 30,427 43,539 7,452 9,207
ROI = return on investment; RRR = relative risk reduction
Table 6b: Maximum threshold for cost efficiency in the personalised price (PEP) and the quality adjusted life-year (QALY) models.
Relative risk reduction 22%
Female Male
SCORE AGLA/PROCAM SCORE AGLA/PROCAM
Cost/event threshold of CHF 200,000 1200 960 940 1840
Cost/QALY threshold of CHF 150,000 2400 1600 2100 3200
Table 7: Area under receiver operating curves by sex, SCORE/PROCAM and region for the detection of VA70.
SCORE
Female Male
Olten 0.757 (95% CI 0.723–0.789) p <0.0001 0.750 (95% CI 0.717–0.780) p <0.0001
Koblenz 0.805 (95% CI 0.773–0.835) p <0.0001 0.820 (95% CI 0.797–0.841) p <0.0001
AGLA/PROCAM
Female Male
Olten 0.736 (95% CI 0.701–0.769) p <0.0001 0.694 (95% CI 0.660–0.727) p <0.0001
Koblenz 0.773 (95% CI 0.739–0.805) p <0.0001 0.777 (95% CI 0.753–0.801) p <0.0001
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tensified preventive medical efforts and the potential for
reclassification of risk with carotid imaging at an afford-
able cost appear inevitable in order to substantially im-
prove the current situation.
Sensitivity of AGLA to detect VA70 in women
As outlined in table 4, an AGLA risk of 4% instead of 10%
is much better suited for the definition of intermediate or
higher risk in Olten area women (sensitivity 33%, speci-
ficity 92%), and current Swiss guidelines may therefore
need further adjustments for women in order to detect at
least 33% instead of only 6% of women having VA70.
To obtain acceptable sensitivities, decision thresholds for
SCORE ought also to be lowered in women to 1–2% and
in men to 3–4% instead of 5%.
Reclassification using carotid ultrasound
Alternatively, we show how carotid ultrasound can be used
to better detect higher-risk subjects defined as being at low
risk by PROCAM or SCORE (table 5). Since in Switzer-
land up to 50% of acute coronary syndromes occur in
healthy persons defined by risk charts to be at low risk [1],
it appears appropriate to filter out high-risk subjects from
the low-risk segment in order to obtain a reclassification to
a higher risk category where more intensive measures of
prevention could be applied.
Reclassification using the Bayes theorem
In this study, the Bayes theorem was used to calculate post-
test probabilities in those with carotid plaque. For this pur-
pose, the sensitivity and specificity of a given TPA in a
patient was entered into the Bayes formula. Using this ap-
proach, in our study primary care subjects were shifted in
7–34% of cases (depending on gender and the pretest prob-
ability used) from low to a higher risk category. The num-
ber of low-risk subjects needed to image ranged between 3
and 15 (table 5).
Cost efficiency of carotid imaging for a price of CHF
100 per examination
All low risk subjects defined with either SCORE or PRO-
CAM had a carotid imaging examination. Those shifted
from low to intermediate or high cardiovascular risk
formed the intervention group, where the effect simulation
allowed for a 50% LDL reduction at a cost of 0.68 CHF/
d (which is the effect of 20 mg rosuvastatin per day,) and
the RRR per 1 mmol/l LDL reduction was 22% (any pa-
tient) and 35% (primary care patient with cardiovascular
risk <20%) in 10 years [17]. This approach allowed us to
calculate several possibilities (table 6a) and the maximum
cost per ultrasound examination that would allow cost ef-
ficiency according to the defined thresholds (table 6b). Us-
ing these assumptions, we found a high cost efficiency
when carotid ultrasound was added to the clinical work-up
in low-risk patients.
Diagnostic accuracy of PROCAM/AGLA and SCORE
As shown in table 7, the AUC as a measure of diagnostic
accuracy showed similar results for the different calcu-
lators (0.75–0.82); however, in men from the Olten area
there was a trend to lower accuracy (0.69).
The validity of carotid ultrasound imaging for cardio-
vascular risk prediction
Imaging carotid arteries to quantify carotid plaque burden
is valid, because carotid TPA accurately predicts cardio-
vascular events, similar to calcifications in coronary arter-
ies [5, 26, 27]. We previously derived our vascular age risk
tool from TPA in 1500 men and women by substitution of
chronological age by vascular age in the PROCAM func-
tion, and we validated this approach externally in a Canadi-
an cohort of 684 primary care subjects with an observation
time of 2.6 years on average and where 13 myocardial in-
farctions occurred [7]: AUC was significantly improved by
0.13 from 0.65 to 0.78 (p = 0.02). Therefore, we were able
to furnish a preliminary validation of our vascular age tool.
Our measurement of plaque area is manufacturer indepen-
dent, encompasses the whole carotid artery from clavicles
to lower jaw (not just 6 cm as described in the PESA study
[28]), does not need any costly software and the tracings
are made in a few minutes. Therefore, TPA has the poten-
tial for widespread use in primary care, since the cost of
ultrasound machines with included software is below EUR
5000 and measurements are very easy to perform. Oth-
ers use 3D imaging of atherosclerotic plaque [28, 29], but
the clinical use is limited by costs, calcified plaque, ven-
dor dependence (Philips iU22 ultrasound system), limited
field of view (imaging length of 3.8 cm with the potential
to miss significant amounts of plaque) and need for spe-
cialised centres to quantify the total plaque volume [28].
Further, the correlation coefficients for 2D-TPA and 3D
plaque imaging are good, whereas the correlation coeffi-
cients for carotid intima-media thickness and 3D plaque
imaging in carotid arteries are very poor [30].
The validity of vascular age
Vascular age has also been used by others as a surrogate
marker for cardiovascular risk, and may be used to replace
chronological age in risk equations. The additional infor-
mation regarding the burden of atherosclerosis derived
from coronary calcifications, TPA and intima-media thick-
ness has recently been reviewed extensively [31]. It is ac-
knowledged that the presence of carotid plaque is a high-
risk cardiovascular finding [13, 32, 33]. The addition of
subclinical markers in cardiovascular risk prediction has
been shown to improve the performance of SCORE [34],
and US and European guidelines recommend treating ath-
erosclerosis detected by means of imaging [35–37].
Limitations
The following limitations have to be addressed. Our vas-
cular age tool was used within a clinical setting as part of
routine measurements by two different observers and the
remarkable congruence of the findings from the two imag-
ing centres may be viewed as a mutual confirmation of our
findings. We examined practice-based subjects in order to
validate currently recommended risk thresholds, since de-
cisions about the intensity of preventive therapy are made
at the practice level. Whether our findings can be gener-
alised to the population level needs to be confirmed; how-
ever, they do call for a better validation of risk predic-
tion tools as also discussed recently in a comprehensive
overview [38]. Finally, VA70 is a highly specific (≈95%)
but poorly sensitive (≈10%) marker for the occurrence of
myocardial infarction [5]. However, if VA70 is used in se-
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rial testing with PROCAM/SCORE as the first test, then
post-test probability increases according to the Bayes the-
orem by a factor of ≈2 [39, 40]. Therefore, when looking
at reclassification of risk, a highly specific marker of risk
is helpful.
Conclusion
In our practice-based middle-aged (40–65 years) and pre-
dominantly low-risk group of 3248 subjects without car-
diovascular disease and without preventive use of statins
and antihypertensive drugs, we found that the prevalence
of old arteries (VA70) was one in eight and that current de-
cision thresholds using PROCAM, AGLA, or SCORE had
a very low sensitivity, especially in women, to detect old
arteries. There are two potential solutions to this problem.
Either intermediate risk is defined as, for example, 5% risk
in 10 years instead of 10% for PROCAM/AGLA, or a re-
classification is applied using ultrasound of carotid imag-
ing as shown in this study. This has the potential to cost-
effectively allocate preventive resources to those estimated
as having low-risk, but have atherosclerosis to an amount
that shifts them from low-risk to a higher cardiovascular
risk category.
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Appendix 1
Supplementary data
Figure S1: Intraobserver variability for total plaque area (M.R.).
Table S1: Percentile value of VA70 in the Arteris (n = 5383) and Tromsø cohorts (n = 6226).
Total plaque area (mm2) Arteris Tromsø
Female 66 80th 99th
Male 108 86th 99th
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